Header Logo

Connection

THOMAS WHEELER to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications THOMAS WHEELER has written about Neoplasm Staging.
THOMAS WHEELER
Connection Strength
0.848
Neoplasm Staging
  1. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.047
  2. [The 1992 TNM classification of T2 prostate cancer predicts pathologic stage and prognosis better than the revised 1997 classification]. Nihon Hinyokika Gakkai Zasshi. 2002 Jul; 93(5):595-601.
    View in: PubMed
    Score: 0.036
  3. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol. 1999 Aug; 12(8):751-5.
    View in: PubMed
    Score: 0.029
  4. Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol. 1998 Oct; 29(10):1119-23.
    View in: PubMed
    Score: 0.028
  5. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998 Aug; 29(8):856-62.
    View in: PubMed
    Score: 0.027
  6. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma. Ann Thorac Surg. 2017 Nov; 104(5):1679-1687.
    View in: PubMed
    Score: 0.026
  7. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142.
    View in: PubMed
    Score: 0.025
  8. Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. J Urol. 2015 Jan; 193(1):58-63.
    View in: PubMed
    Score: 0.021
  9. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation. Arch Pathol Lab Med. 2014 Oct; 138(10):1387-405.
    View in: PubMed
    Score: 0.021
  10. Clinical relevance of the individual prostate cancer focus. Cancer Invest. 1994; 12(4):425-37.
    View in: PubMed
    Score: 0.020
  11. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. J Mol Diagn. 2013 Mar; 15(2):270-9.
    View in: PubMed
    Score: 0.019
  12. Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int. 2011 Oct; 108(7):1074-85.
    View in: PubMed
    Score: 0.016
  13. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan; 178(1):79-87.
    View in: PubMed
    Score: 0.016
  14. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol. 2011 Jan; 24(1):6-15.
    View in: PubMed
    Score: 0.016
  15. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011 Jan; 24(1):16-25.
    View in: PubMed
    Score: 0.016
  16. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011 Jan; 24(1):39-47.
    View in: PubMed
    Score: 0.016
  17. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011 Jan; 24(1):26-38.
    View in: PubMed
    Score: 0.016
  18. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011 Jan; 24(1):48-57.
    View in: PubMed
    Score: 0.016
  19. Staging of prostate cancer. Value of ultrasonography. Urol Clin North Am. 1989 Nov; 16(4):713-34.
    View in: PubMed
    Score: 0.015
  20. Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med. 2009 Oct; 133(10):1568-76.
    View in: PubMed
    Score: 0.015
  21. Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol. 2008 Oct; 32(10):1503-12.
    View in: PubMed
    Score: 0.014
  22. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008 Oct; 32(10):1532-9.
    View in: PubMed
    Score: 0.014
  23. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007 Dec; 178(6):2260-7.
    View in: PubMed
    Score: 0.013
  24. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther. 2006 Apr; 13(4):716-28.
    View in: PubMed
    Score: 0.012
  25. Prognostic and predictive factors in prostate cancer: historical perspectives and recent international consensus initiatives. Scand J Urol Nephrol Suppl. 2005 May; (216):8-19.
    View in: PubMed
    Score: 0.011
  26. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl. 2005 May; (216):34-63.
    View in: PubMed
    Score: 0.011
  27. Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol. 2004 Aug; 172(2):508-11.
    View in: PubMed
    Score: 0.010
  28. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology. 2004 Jun; 63(6):1191-7.
    View in: PubMed
    Score: 0.010
  29. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol. 2004 May; 171(5):1844-9; discussion 1849.
    View in: PubMed
    Score: 0.010
  30. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004 May 01; 22(9):1655-63.
    View in: PubMed
    Score: 0.010
  31. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004 Mar 15; 10(6):1992-9.
    View in: PubMed
    Score: 0.010
  32. Recurrent hypercalcemia due to ectopic production of parathyroid hormone-related protein and intact parathyroid hormone in a single patient with multiple malignancies. Endocr Pract. 2004 Mar-Apr; 10(2):125-8.
    View in: PubMed
    Score: 0.010
  33. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol. 2003 Nov; 170(5):1792-7.
    View in: PubMed
    Score: 0.010
  34. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res. 2003 Oct 01; 63(19):6244-51.
    View in: PubMed
    Score: 0.010
  35. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 2003 Sep 15; 63(18):5874-8.
    View in: PubMed
    Score: 0.010
  36. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003 Oct 01; 21(19):3573-9.
    View in: PubMed
    Score: 0.010
  37. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 2003 Aug 01; 63(15):4662-70.
    View in: PubMed
    Score: 0.010
  38. IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):184-91.
    View in: PubMed
    Score: 0.009
  39. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
    View in: PubMed
    Score: 0.009
  40. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol. 2002 Nov; 168(5):2011-5.
    View in: PubMed
    Score: 0.009
  41. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol. 2002 Apr 15; 20(8):2025-30.
    View in: PubMed
    Score: 0.009
  42. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol. 2002 Mar; 167(3):1475-81.
    View in: PubMed
    Score: 0.009
  43. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002 Feb; 167(2 Pt 1):528-34.
    View in: PubMed
    Score: 0.009
  44. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer. 2001 Sep 15; 92(6):1475-83.
    View in: PubMed
    Score: 0.008
  45. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol. 2001 Jun 01; 19(11):2856-64.
    View in: PubMed
    Score: 0.008
  46. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
    View in: PubMed
    Score: 0.008
  47. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001 Jan; 32(1):74-80.
    View in: PubMed
    Score: 0.008
  48. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.008
  49. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 2000 Oct 15; 60(20):5857-61.
    View in: PubMed
    Score: 0.008
  50. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology. 2000 Sep 01; 56(3):423-9.
    View in: PubMed
    Score: 0.008
  51. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
    View in: PubMed
    Score: 0.007
  52. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998 May 20; 90(10):766-71.
    View in: PubMed
    Score: 0.007
  53. Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer. 1998 Jan 01; 82(1):168-75.
    View in: PubMed
    Score: 0.007
  54. Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases. Clin Cancer Res. 1997 Aug; 3(8):1389-97.
    View in: PubMed
    Score: 0.006
  55. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol. 1997 Jun; 157(6):2212-8.
    View in: PubMed
    Score: 0.006
  56. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997 Feb 01; 79(3):528-37.
    View in: PubMed
    Score: 0.006
  57. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996 Sep; 156(3):1059-63.
    View in: PubMed
    Score: 0.006
  58. Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen. Cancer. 1996 Jul 15; 78(2):366-8.
    View in: PubMed
    Score: 0.006
  59. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 1996 Jul; 48(1):47-57.
    View in: PubMed
    Score: 0.006
  60. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995 Nov; 154(5):1818-24.
    View in: PubMed
    Score: 0.006
  61. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995 Oct; 1(10):1111-8.
    View in: PubMed
    Score: 0.006
  62. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol. 1994 Nov; 152(5 Pt 2):1714-20.
    View in: PubMed
    Score: 0.005
  63. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol. 1994 Nov; 152(5 Pt 2):1843-9.
    View in: PubMed
    Score: 0.005
  64. The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer. 1994 Jul 01; 74(1):104-14.
    View in: PubMed
    Score: 0.005
  65. Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation. Prostate. 1993; 23(4):271-81.
    View in: PubMed
    Score: 0.005
  66. Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy. Urology. 1992 Apr; 39(4):358-63.
    View in: PubMed
    Score: 0.004
  67. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol. 1991 Nov; 68(5):499-509.
    View in: PubMed
    Score: 0.004
  68. DNA ploidy by image analysis of individual foci of prostate cancer: a preliminary report. Cancer Res. 1991 Aug 01; 51(15):4084-9.
    View in: PubMed
    Score: 0.004
  69. Transrectal ultrasonography in stage A prostate cancer: detection of residual tumor after transurethral resection of prostate. J Urol. 1991 Aug; 146(2):366-71.
    View in: PubMed
    Score: 0.004
  70. The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol. 1991 Feb; 145(2):324-8; discussion 328-9.
    View in: PubMed
    Score: 0.004
  71. The appearance of prostate cancer on transrectal ultrasonography: correlation of imaging and pathological examinations. J Urol. 1989 Jul; 142(1):76-82.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.